Q2 2026 Swedish Orphan Biovitrum AB (publ) Earnings Call Transcript
Key Points
- Swedish Orphan Biovitrum AB (BIOVF) reported a strong Q2 with a 29% revenue growth at constant exchange rates.
- The company increased its full-year outlook based on strong first-half performance, reflecting confidence in continued delivery.
- Positive data from the REDUCE-2 trial for pozdeutinurad was announced, demonstrating meaningful urate reduction.
- Altuvoct showed strong growth in haemophilia A prophylaxis, with sales increasing significantly year-over-year.
- The company is advancing its pipeline with multiple programs, including the initiation of the EMBRACE-II study for Gamifant in interferon gamma-driven sepsis.
- Swedish Orphan Biovitrum AB (BIOVF) received a complete response letter from the FDA for NASP related to manufacturing issues.
- R&D expenses increased by 47% at constant exchange rates, driven by the addition of new development programs.
- The launch of Aspaveli in nephrology showed a slight decline in sales compared to Q1, raising concerns about its growth trajectory.
- The company faces high competition in the market, particularly from Arrowhead in the area of acute pancreatitis.
- There is uncertainty regarding the timeline for NASP resubmission, as the post-CRL FDA meeting has not yet been scheduled.
()-
Hello, everyone. This is Guido Oelkers, CEO of Sobi. We are delighted to welcome you to the second quarter and half year of 2026 conference call for investors and analysts. Our presentation was posted on sobi.com earlier today. Please turn to slide number 2.
We would like to remind you of the usual provisions on statements about expectations and projections of future events. Unless stated otherwise, we are making comments that mostly relate to the second quarter at constant currency exchange rates and in million Swedish krona. Please turn to the next slide.
Today, we plan to cover the key aspects of our Q2 report. I'm joined by Henrik Stenqvist, our CFO; and Lydia Abad-Franch, Head of R&D and Chief Medical Officer. We plan to review this presentation first and have Q&A until around 3:00 PM today, Central Eastern European time. (Operator Instructions) Please turn to slide number 4.
It's about the key takeaways for Q2. Let me start with the key messages from what
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
